5Vote!
San Fransisco Chronicle (Free subscription) | 10/21/2009
Bristol-Myers Squibb Co., the world's No. 15 drug maker by revenue, reports earnings for the third quarter on Thursday morning. The following is a summary of key developments and analyst opinion related to the period. OVERVIEW: Growing competition for its top... Sponsored Topics: Bristol-Myers Squibb - Bristol - England - Society and Culture - Bristol-Myers Squibb Co
3Vote!
Value Expectations - (Free subscription) | 09/03/2009
Related: AEP , BIG , BMY , BSX , CAG , ERTS , HRS , SEE , STZ , VZ Fidelity has a fund called the Low Priced Stock fund that only contains stocks with a price of below $35 a share which has been successful in the past. Following a similar strategy ValueExpectations.com has published 2 articles containing attractive stocks under $35 as a starting place for investor’s looking for potential investment...
1Vote!
ShoppingBlog.com (Free subscription) | 08/14/2009
U.S researchers have discovered a compound which could revolutionize breast cancer treatment. The compound kills the breast cancer stem cells that are responsible for growing new cancer cells. They are called "master cells" and before this scientists have been unable to kill them. "There is a lot of evidence to suggest now that these cells are responsible for many of the recurrences...
3Vote!
Business Wire (Free subscription) | 08/04/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
6Vote!
PharmaGossip (Free subscription) | 08/03/2009
The US government has declined to intervene in a whistleblower lawsuit accusing AstraZeneca PLC (AZN) and Bristol-Myers Squibb Co. (BMY) of bribing a pharmacy-benefits manager to purchase their drugs and hiding price discounts from the government. The suit was brought by a former vice president of Medco Health Solutions Inc. (MHS) on behalf of the U.S. government, 11 states and the District of Columbia....
2Vote!
MSNBC.com (Free subscription) | 08/01/2009
Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.
4Vote!
Financial24 (Free subscription) | 07/31/2009
WASHINGTON, July 31 - AstraZeneca PLC and Bristol-Myers Squibb Co won U.S approval on Friday to sell a new diabetes drug called Onglyza . The Food and Drug Administration said it was requiring a post-approval study to evaluate the drug's cardiovas ...
6Vote!
San Fransisco Chronicle (Free subscription) | 07/31/2009
Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC. The Food and Drug Administration said it approved the companies' drug Onglyza to reduce blood sugar levels in... Sponsored Topics: Bristol-Myers Squibb - AstraZeneca - U.S. Food and Drug Administration - Food and Drug Administration - Blood sugar
5Vote!
San Diego Union (Free subscription) | 07/31/2009
Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.
1Vote!
kansascity.com (Free subscription) | 07/31/2009
Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.
3Vote!
SeekingAlpha ETFs (Free subscription) | 07/24/2009
Michael Johnston submits: Biotech ETFs, which saw tremendous gains earlier this week on news that Human Genome Science Inc.’s ( HGSI ) lupus drug had passed a key clinical trial hurdle , were big winners again on Thursday. The driver this time: news that antibody technology specialist Medarex had agreed to be acquired by Bristol-Myers Squibb Co. ( BMY ) at close to a 90% premium. While funds...
5Vote!
The Washington Times (Free subscription) | 07/24/2009
Encouraging news on home sales and better-than-expected earnings poured more rocket fuel on Wall Street's nine-day, 11 percent rally Thursday, sending the Dow Jones Industrial Average nearly 188 points higher to close at its high for the year. The rally began early in the day after investors learned that home resales increased for the third month in a row in June. Several companies reported eye-popping...
The last article published by a user on Bristol-Myers Squibb Co. :
2Vote!
pickpennystocks | 07/23/2009
WePickPennyStocks.com is pleased to alert investors of stocks on the move. Sign up to receive free Stock Alerts The Dow Jones Industrial Average reached 9000 on Thursday for the first time since January. The Dow rose 173.14, or 1.95 percent, to 9054.40 in morning trading. The Dow hasn’t reached the 9000 plateau since Jan. 6. The increase is due partly because of positive...
Videos